Dihydropyrazolo[3,4-d]thieno-[2,3-B]pyridinone inhibitors of B7-1
AssigneeWyeth
InventorsNeal Jeffrey Green, Lihren Chen, Steve Yikkai Tam
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease. 1
Claims20
A compound of formula I
- 15
- wherein
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3-C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
- R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
- phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
- naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
- C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
- heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
- R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
- R5 is H, C1-C3alkyl or haloalkyl;
- R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- n is 0 or an integer of 1 or 2;
- R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- and
- R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
- phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
- benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
- pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
- R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A method for the treatment of an immune disorder related to or affected by the immune regulatory protein B7-1 which comprises providing a patient in need thereof an immunotherapeutically effective amount of a compound of formula I
- 16
- wherein
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3-C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
- R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
- phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
- naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
- C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
- heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
- R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
- R5 is H, C1-C3alkyl or haloalkyl;
- R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl,
- C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- n is 0 or an integer of 1 or 2;
- R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and qR25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl,
- C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- and
- R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
- phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
- benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
- pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
- R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- 17
- wherein
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
- R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
- phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
- naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
- C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
- heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
- R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
- R5 is H, C1-C3alkyl or haloalkyl;
- R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl,
- C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- n is 0 or an integer of 1 or 2;
- R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- and
- R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
- phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
- benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
- pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
- R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A process for the preparation of a compound of formula I
- 18
- wherein
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3-C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
- R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
- phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
- naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
- C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
- heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
- R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
- R5 is H, C1-C3alkyl or haloalkyl;
- R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- n is 0 or an integer of 1 or 2;
- R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- and
- R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
- phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
- benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
- pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
- R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S;
- or
- which process comprises reacting a compound of formula VI
- 19
- wherein R1, R2 and R4 are described hereinabove with a hydrazine, R3NHNH2, to give a 3-hydrazinylthieno-[2,3-b]pyridine intermediate;
- and cyclizing said intermediate to give the desired compound of formula I.
Dependencies are inferred from the claim text.